<DOC>
	<DOCNO>NCT00603096</DOCNO>
	<brief_summary>The aim randomize control trial compare improvement diurnal PaCO2 OHS patient one month NIV treatment depend upon tool use adjusting setting . In one arm setting adjust use nocturnal oxygen SaO2 PaCO2 awaken whereas arm patient benefit complete polysomnography NIV .</brief_summary>
	<brief_title>Use Polysomnography Non-Invasive Ventilation Settings ' Optimization</brief_title>
	<detailed_description>Initiation NIV treatment implies technical adjustment ( choice mask ventilator ) , also patient education nurse medical staff . The setting generally adjust daytime awake patient . The appropriateness setting generally optimal sleep many respiratory event ( hypopnoea , apnea , leak , desynchronization , glottic closure ) may occur NIV reduce effectiveness treatment . These nocturnal abnormality routinely evaluate measure consequence , i.e . oxygen desaturation level PaCO2 wake . Some team propose well characterize happen use NIV sleep use polysomnography ( PSG ) . The precise characterization residual event treatment may allow optimize ventilator setting .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Hypoventilation</mesh_term>
	<mesh_term>Obesity Hypoventilation Syndrome</mesh_term>
	<criteria>Patient male female , age 20 75 year Patient OHS stable condition , BMI &gt; 32 kg/m2 PaCO2 &gt; 6 kPa diurnal spontaneous breathe without cause alveolar hypoventilation Patient affiliate social security insurance Having give write informed consent participate study Patients inherent chronic obstructive pulmonary disease ( COPD ) FEV1 Forced Vital Capacity ( FVC ) ratio le 70 % Patients suffer heart failure periodic breathing Associated Neurological Diseases , evolve rapidly , lead dependency daily activity Unbalanced Psychiatric Diseases Patients respiratory decompensation month precede study Patients autonomous use NIV Pacemaker patient , constitute contraindication magnetic stimulation Sensitive subject , accordance article L 11216 French Public Health Code Patients long term steroid antiinflammatory drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>